Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер unknown, С. 106312 - 106312
Опубликована: Окт. 1, 2024
Язык: Английский
Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер unknown, С. 106312 - 106312
Опубликована: Окт. 1, 2024
Язык: Английский
Molecular Therapy — Nucleic Acids, Год журнала: 2025, Номер 36(1), С. 102457 - 102457
Опубликована: Янв. 18, 2025
Язык: Английский
Процитировано
4Journal of Nanobiotechnology, Год журнала: 2025, Номер 23(1)
Опубликована: Апрель 17, 2025
Inner ear disorders are among the predominant etiology of hearing loss. The blood-labyrinth barrier limits ability drugs to attain pharmacologically effective concentrations within inner ear; consequently, delivering systemically is insufficient for effectively treating disorders. Hence, it imperative create efficient, minimal or non-invasive methods administering ear. However, development such a system hindered by three main factors: anatomical unavailability, lack sustained drug delivery, and individual variability. Advances in biomaterials technology have created new opportunities overcoming existing barriers, offering great hope treatment Hydrogel- nanoparticle-based delivery systems can carry targeted designated locations long-term, release. Furthermore, range devices, including microneedles, micropumps, cochlear implants, when paired with biomaterials, enhance ear, making more effective. Therefore, biomaterial-based offer possibility extensive clinical uses promise restore millions patients
Язык: Английский
Процитировано
0Biosensors and Bioelectronics, Год журнала: 2025, Номер 286, С. 117588 - 117588
Опубликована: Май 15, 2025
Advancements in inner ear theragnostics are critical for addressing the pervasive challenges of diagnosing and treating hearing balance disorders, which significantly impact quality life. This paper reviews biosensors devices that leverage advanced functional nanomaterials, microfabrication techniques, nano-biotechnology to enhance theragnostic applications ear. The highlights development diverse electromechanical, electrochemical, biomarker sensors theragnostics. Electromechanical replicate cochlear vestibular sensory structures through bioinspired designs, while electrochemical used measure level ions chemicals fluid, providing insights into health disease organs. Biomarker focus on screening diseases early detection correlated biomarkers based point care diagnostics. study also examines use microfluidic with elements provide a compact integrated model fluid-filled cochlea. In addition, delivery strategies, including targeted drug systems nanocarriers explored their ability improve penetration distribution therapeutics within importance pharmacokinetics post-treatment monitoring as indicators assessing efficacy micro/nanotechnology-based approaches. By consolidating these innovations, this work offers comprehensive framework advancing otology, paving way novel diagnostic tools, effective treatments, future clinical applications.
Язык: Английский
Процитировано
0Advanced Therapeutics, Год журнала: 2025, Номер unknown
Опубликована: Май 16, 2025
Abstract Hearing loss (HL) is a significant global health challenge, affecting billions of people and severely impacting quality life. While traditional interventions such as hearing aids cochlear implants mitigate symptoms, they fail to address the underlying causes HL, especially in cases involving severe damage hair cells or spiral ganglion neurons. Emerging therapeutic strategies, including biomaterials, nanocarrier drug delivery systems, gene therapy, extracellular vesicle (EV)‐based approaches, have demonstrated potential promoting inner ear regeneration restoring auditory function. Biomaterials mimic matrix guide cell regeneration, while nanocarriers EVs enhance targeted sustained agents. Gene therapy offers opportunities correct genetic mutations, addressing hereditary HL. However, challenges anatomical complexity cochlea, blood‐labyrinth barrier, limited regenerative capacity persist. Future research must focus on scalable, biocompatible, clinically safe systems advance clinical translation these innovative therapies. This review underscores integrating strategies develop effective long‐lasting treatments for
Язык: Английский
Процитировано
0Current Medical Science, Год журнала: 2025, Номер unknown
Опубликована: Май 21, 2025
Язык: Английский
Процитировано
0Neuroscience Bulletin, Год журнала: 2025, Номер unknown
Опубликована: Май 27, 2025
Язык: Английский
Процитировано
0Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер unknown, С. 106312 - 106312
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
0